ADRENACLICK (epinephrine) by Fresenius Kabi is adrenergic alpha-agonists [moa]. First approved in 2003.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
ADRENACLICK is an epinephrine auto-injector administered intramuscularly or subcutaneously for emergency treatment of anaphylaxis and severe allergic reactions. It works as an alpha-adrenergic agonist, rapidly activating sympathetic nervous system receptors to counteract anaphylactic shock. The product is indicated for patients at risk of life-threatening allergic reactions requiring immediate emergency intervention.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward defensive positioning.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Worked on ADRENACLICK at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ADRENACLICK offers limited career growth potential given the LOE approaching lifecycle stage and absence of linked job openings. Professionals on this product should expect restructuring, potential redundancy, and pressure to transition to higher-priority assets or external opportunities.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo